NovaGo Therapeutics raised €26M in a Series B round in Sep 2026. The company is based in Schlieren, Switzerland. Investors in the round: Neurimmune Holding, new investors, Pureos Ventures and 2 others. Data as of 21 Sept 2026.
Confidence is the weaker of amount-FX and source evidence (the cascade rule). See methodology.
